BioRegenx, Inc. engages in the research, development, and commercialization of dietary supplements, medical devices, software, and contactless diagnostic technologies in the United States and internationally. The company offers DocSun AI engine, which integrates with a ballistocardiograph that detects an individual's heartbeat; TruScan.AI mobile app for additional health indications; VitalWellness app for DNA and epigenetics platform; and Endocalyx Pro, a dietary supplement targeting microvascular capillary health. It also provides MyBodyRx, a supplement; GlycoCheck software and medical devices; hydrogen water products and health and wellness devices, such as pulsed electro-magnetic field devices; StimaWELL and ReLounge electronic muscle stimulation therapy devices; and Findit.com, a social media content management platform. The company sells its products through a direct selling channel to health professionals and research organizations. BioRegenx, Inc. is headquartered in Chattanooga, Tennessee.
0 transactions — 0 buys and 0 sales reported by BioRegenx, Inc. executives.
0 institutional funds report a position on BRGX in their latest SEC quarterly filing.
Beyond raw data, we aggregate and score every smart money signal to give you a unique view.
8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.
Detection of clustered purchases or sales by several executives in the same stock.
Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.
NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.
Spot marked changes in search interest around the stocks being followed.
Create your watchlist and receive a brief of events affecting your tickers.
This public page only shows a preview. The full analysis of BRGX on the Kairos Insider dashboard includes:
Free signup · Pro €19/month or €190/year